This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Reports for Target, Illumina & T-Mobile US
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Target (TGT), Illumina (ILMN) and T-Mobile US (TMUS).
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Zacks Equity Research
Sector ETF report for FMAT
DuPont to Sell Silicon Carbide Wafer Business to SK Siltron
by Zacks Equity Research
The divestment is in sync with DuPont's (DD) strategy of active portfolio management.
Is DuPont de Nemours (DD) a Great Pick for Value Investors?
by Zacks Equity Research
DuPont de Nemours (DD) stock may be a good choice for value-oriented investors right now from multiple angles.
DuPont's (DD) Earnings Top, Sales Trail Estimates in Q2
by Zacks Equity Research
DuPont (DD) gains from cost and pricing actions in Q2. The company raises adjusted earnings per share guidance for 2019.
DuPont's (DD) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
DuPont's (DD) Q2 adjusted earnings of 97 cents per share topped the Zacks Consensus Estimate of 86 cents.
DuPont (DD) Warms Up to Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Our proven model does not show that DuPont (DD) is likely to beat estimates this quarter.
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Zacks Equity Research
Sector ETF report for FMAT
Analysts Estimate DuPont (DD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DuPont (DD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why DuPont (DD) Could Be Positioned for a Slump
by Zacks Equity Research
DuPont (DD) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
New Strong Sell Stocks for June 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
DuPont Launches EverpreX Soybean Herbicide to Protect Crops
by Zacks Equity Research
DuPont (DD) introduces EverpreX herbicide, a crop protection solution to fight resistant weeds for safeguarding yield protection.
Monsanto's Tech Improvements to Boost Innovation Platform
by Zacks Equity Research
Monsanto (MON) offers advanced Climate FieldView platform and NemaStrike technology for 2018 crop season. It intends to supply more Roundup Ready 2 Xtend soybeans in the United States.
Dow Chemical, TeselaGen Team Up to Expand Biodesign Platform
by Zacks Equity Research
Dow Chemical's (DOW) fully owned subsidiary Dow AgroSciences and TeselaGen collaborates to produce a state-of-the-art biological design automation platform that can expedite discovery work.
Dow, Saudi Aramco to Restructure Ownership in Sadara JV
by Zacks Equity Research
The potential ownership restructuring would increase Dow Chemical's (DOW) equity stake in Sadara JV to 50%.
DuPont to Exhibit Food Solutions Addressing Health Issues
by Zacks Equity Research
DuPont (DD) has come up with local food solutions that will be introduced at Food Ingredients Asia 2017 in response to health and nutrition concerns in Southeast Asia.
Why Is DuPont (DD) Down 4.7% Since the Last Earnings Report?
by Zacks Equity Research
DuPont (DD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DuPont (DD) to Upgrade Probiotics Facility in Wisconsin
by Zacks Equity Research
DuPont's (DD) Nutrition & Health segment announced an expansion of its probiotics pilot facility in Madison, WI worth $10 million which will strengthen DuPont's position as a leading player in the probiotics industry.
Trump Passes Order to Fix U.S. Infrastructure: ETFs in Focus
by Zacks Equity Research
President Trump rolls back environmental policies in order to expedite Infrastructure projects.
Monsanto (MON) Signs Deal with ToolGen for CRISPR Technology
by Zacks Equity Research
Monsanto Company (MON) enhances genome-editing tools portfolio by signing a deal with ToolGen, in order to secure intellectual property rights for the latter's CRISPR technology.
FMC Corp (FMC) Touches New 52-Week High: What's Driving It?
by Zacks Equity Research
Strength in the Lithium unit and upbeat prospects stemming from the planned acquisition of DuPont's assets are driving FMC Corp. (FMC).
Dow Chemical's (DOW) New $100M Center to Focus on Innovation
by Zacks Equity Research
Dow Chemical's (DOW) new $100 million innovation center will drive innovation and create growth synergies at intersection of organic chemistry and silicone science.
DuPont's Granular Buyout to Drive Profits for Farmers
by Zacks Equity Research
DuPont (DD) signs a definitive agreement to purchase Granular with an objective to help farmers operate more profitable businesses.
Dow Chemical, Arcadia Tie Up to Develop Wheat Traits
by Zacks Equity Research
Dow Chemical's (DOW) unit Dow AgroSciences and Arcadia Biosciences collaborate to develop and commercialize improved wheat quality trait in North America.
Dow Chemical, DuPont Set Date for Merger Completion
by Zacks Equity Research
The mega-merger of Dow Chemical (DOW) and DuPont is set to close on Aug 31.